Simon Call
Overview
Explore the profile of Simon Call including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ronnacker J, Grau M, Klasmeier M, Klesse C, Baldauf H, Abert S, et al.
Blood
. 2025 Jan;
PMID: 39813679
Apolipoprotein E (APOE) has multiple functions in metabolism and immunoregulation. Its common germline variants APOE2, APOE3 and APOE4 give rise to three functionally distinct gene products. Previous studies reported yin-yang...
2.
Ronnacker J, Urbahn M, Reicherts C, Kolloch L, Berning P, Sandmann S, et al.
Br J Haematol
. 2024 Jun;
205(1):280-290.
PMID: 38831752
For patients with relapsed or refractory AML, sequential conditioning prior to allogeneic stem cell transplantation (alloSCT) is an established and potentially curative treatment option. Early response to treatment during conditioning...
3.
Berning P, Kolloch L, Reicherts C, Call S, Marx J, Floeth M, et al.
Bone Marrow Transplant
. 2024 May;
59(8):1097-1106.
PMID: 38702400
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a standard treatment for patients with AML and MDS. The combination of fractionated total body irradiation(8GyTBI/Flu) with fludarabine is an established conditioning regimen,...
4.
Berning P, Shumilov E, Maulhardt M, Boyadzhiev H, Kerkhoff A, Call S, et al.
Hemasphere
. 2024 Mar;
8(3):e54.
PMID: 38510993
CD19-directed chimeric antigen receptor (CAR)-T cell therapy has become a standard treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). While the benefits of CAR-T cell treatment are clear in...
5.
Shaforostova I, Call S, Evers G, Reicherts C, Angenendt L, Stelljes M, et al.
EJHaem
. 2024 Feb;
5(1):93-104.
PMID: 38406551
Flow cytometry-based immunophenotyping is a mainstay of diagnostics in acute myeloid leukaemia (AML). Aberrant CD56 and T-cell antigen expression is observed in a fraction subset of AML cases, but the...
6.
Wenge D, Wethmar K, Klar C, Kolve H, Sauer T, Angenendt L, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158832
Prognosis of elderly ALL patients remains dismal. Here, we retrospectively analyzed the course of 93 patients > 55 years with B-precursor ( = 88) or T-ALL ( = 5), who...
7.
Wullenkord R, Reicherts C, Mikesch J, Marx J, Wethmar K, Albring J, et al.
Ann Hematol
. 2020 Aug;
100(2):587-589.
PMID: 32829460
No abstract available.
8.
Wethmar K, Matern S, Esseling E, Angenendt L, Pfeifer H, Bruggemann M, et al.
Bone Marrow Transplant
. 2020 Feb;
55(7):1410-1420.
PMID: 32001801
Relapse after allogeneic haematopoietic stem cell transplantation (SCT) is a major cause of death in patients with acute lymphoblastic leukaemia (ALL). Here, we retrospectively analysed the contributions of lineage-sorted donor...